![]() |
||
|
|
Hypertension Diagnostics
Provides ST. PAUL, MN – December 5, 2001 – Hypertension Diagnostics, Inc. (NASDAQ SmallCap: HDII) announced today that Pfizer Pharmaceuticals Group, a division of Pfizer, Inc. (NYSE: PFE), headquartered in New York City, has purchased additional units of HDI’s non-invasive HDI/PulseWave™ CR-2000 Research CardioVascular Profiling System for use in a previously announced multi-center cardiovascular drug research trial. Greg H. Guettler, President of HDI, said, “We are very pleased that Pfizer has expanded the scope of its research trial and that HDI is a key component of that expansion." |
|
|
CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Investor Relations: Jens Dalsgaard and Tony Altavilla, Return
to the Main HDI Newsroom
|
||
|
Copyright © 2007 Hypertension Diagnostics, Inc |
||